Suppliers / Symed Labs

Symed Labs

India 403 employees Updated 9 July 2026

Symed Labs is an API manufacturer based in India. It holds 60 active US drug master files and 20 valid CEPs. Its filings concentrate with MINSA (CR) and CDSCO (India). Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 25 April 2025 as VAI. Customs aggregates show $18.8M of exports covering 495 molecules to 52 destinations in 2025.

60
active US DMFs
20
valid CEPs
5
registered plants 5 with an FDA FEI number
3
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
5 of 5 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 25 April 2025 VAI US FDA
  • 6 December 2024 VAI US FDA
  • 2 February 2024 NAI US FDA
  • 28 July 2018 VAI US FDA
  • 11 May 2018 VAI US FDA
  • 4 May 2018 VAI US FDA
  • 8 December 2017 VAI US FDA
  • 6 November 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Nalgonda, India 3012725393
Hyderabad, India 3005739922
Yadadri Bhuvangiri, India 3015443266
Sangareddy, India 3007164063
Medchal-Malkajgiri, India 3005522065

What they file, and where

Molecule Regulators Docs
Linezolid SFDA (Saudi Arabia), US FDA 9
Hydroxyzine EDQM, US FDA 5
Rivaroxaban EDQM, SFDA (Saudi Arabia), US FDA 5
Bilastine US FDA 4
Brimonidine EDQM, SFDA (Saudi Arabia), US FDA 4
Deferasirox EDQM, SFDA (Saudi Arabia), US FDA 4
Ezetimibe US FDA 4
Ketorolac EDQM, SFDA (Saudi Arabia), US FDA 4
Amisulpride EDQM, SFDA (Saudi Arabia) 3
Hydroxychloroquine EDQM, US FDA 3
Show all 30 molecules on file
Iron Sucrose SFDA (Saudi Arabia), US FDA 3
Levocetirizine Dihydrochloride EDQM, SFDA (Saudi Arabia) 3
Modafinil EDQM, US FDA 3
Prucalopride SFDA (Saudi Arabia), US FDA 3
Tizanidine EDQM, US FDA 3
Carbinoxamine US FDA 2
Dapoxetine SFDA (Saudi Arabia) 2
Dronedarone US FDA 2
Eszopiclone US FDA 2
Iloperidone US FDA 2
Lanthanum Carbonate US FDA 2
Levocetirizine US FDA 2
Meclizine US FDA 2
Meprobamate US FDA 2
Otilonium Bromide US FDA 2
Phentermine US FDA 2
Sertraline US FDA 2
Sucrose US FDA 2
Vortioxetine US FDA 2
Carvedilol EDQM 1

Also appears on these molecule pages

Show 1 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 2 None
CDSCO (India) 1 None
EMA None 5
US FDA None 3

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $7.2M 41
2025 Not reported $18.8M 52

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Symed Labs comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 6 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 25 April 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts